@RheumNow #RNL2024 Winthrop: JAKi similar for opportunistic disease, but higher risk for Herpes Zoster than other therapies Deucravacitinib - lower HZ reported, but younger age. Will see if this holds case in more studies https://t.co/Nd5LitAI3R